Rituximab based therapy followed by autologous stem cell transplantation leads to superior outcome and high rates of PCR negativity in patients with indolent B-cell lymphoproliferative disorders

References

• Donovan JW, Ladetto M, Zou G et al. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood 2000; 95: 2651–2658.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Freedman AS, Neuberg D et al. Immunologic purgingof marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525–1533.
   PubMed Web of Science ®Google Scholar
• Corradini P, Astolfi M, Cherasco C et al. Molecular monitoring ofminimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997; 89: 724–731.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bc1-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449–3457.
   PubMed Web of Science ®Google Scholar
• Zwicky CS, Maddocks AB, Andersen N, Gribben JG. Eradicationof polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation. Blood 1996; 88: 3314–3322.
   PubMed Web of Science ®Google Scholar
• Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up ofautologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325–3333.
   PubMed Web of Science ®Google Scholar
• Brown JR, Feng Y, Gribben JG et al. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 2007; 13: 1057–1065.
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188–2195.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemother-apy. J Clin Oncol 1999; 17: 268–276.
   PubMed Web of Science ®Google Scholar
• Montoto S, Moreno C, Domingo-Domenech E et al. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. Haematologica 2008; 93: 207–214.
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Lazzari M, Manzoni C et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99: 856–862.
   PubMed Web of Science ®Google Scholar
• Buckstein R, Imrie K, Spaner D et al. Stem cell function and engraftment is not affected by 'in vivo purging' with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 1999; 26: 115–122.
   PubMed Web of Science ®Google Scholar
• Galimberti S, Morabito F, Guerrini F et al. Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. Br J Haematol 2003; 120: 405–412.
   PubMed Web of Science ®Google Scholar
• Lee MS, Chang KS, Cabanillas F, Freireich EJ, Trujillo JM, Stass SA. Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science 1987; 237: 175–178.
   PubMed Web of Science ®Google Scholar
• Ott MM, Helbing A, Ott G et al. bcl-1 rearrangement and cyclin D1 protein expression in mantle cell lymphoma. JPathol 1996; 179: 238–242.
   Google Scholar
• Deane M, McCarthy KP, Wiedemann LM, Norton JD. An improved method for detection of B-lymphoid clonality by polymerase chain reaction. Leukemia 1991; 5: 726–730.
   PubMed Web of Science ®Google Scholar
• Cerny J, Slavickova A, Krepelova A, Trneny M, Karban J, Klener P. Biallelic IgH rearrangements in patients with indolent lympho-proliferative disorders: molecular and practical implications. J Cell Physiol 2004; 199: 217–226.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning Si, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Greyer M et al. National Cancer Institute-sponsored Working Group guidelines for chronic lym-phocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Statist Assoc 1958; 53: 457–481.
   Web of Science ®Google Scholar
• Gribben JG. Attainment of molecular remission: a worthwhile goal? J Clin Oncol 1994; 12: 1532–1534.
   PubMed Web of Science ®Google Scholar
• Liu Y, Hernandez AM, Shibata D, Cortopassi GA. BCL2 translocation frequency rises with age in humans. Proc Natl Acad Sci USA 1994; 91: 8910–8914.
   PubMed Web of Science ®Google Scholar
• Price CG, Meerabux J, Murtagh S et al. The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J Clin Oncol 1991; 9: 1527–1532.
   PubMed Web of Science ®Google Scholar
• Ladetto M, De Marco F, Benedetti F et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008; 111: 4004–4013.
   PubMed Web of Science ®Google Scholar
• Rohatiner AZ, Price CG, Arnott S et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation of remission in patients with follicular lymphoma. Ann Oncol 1991; 2 Suppl 2: 147–150.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Brice P, Delarue R et al. Effect of rituximab and/or high-dose therapy with autotransolant at time of relapse in patients with follicular lymphoma. Blood 2007; 110: 120A.
   Web of Science ®Google Scholar
• Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864–869.
   PubMed Web of Science ®Google Scholar
• Corradini P, Ladetto M, Zallio F et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004; 22: 1460–1468.
   PubMed Web of Science ®Google Scholar
• Galimberti S, Guerrini F, Morabito F et al. Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab. Bone Marrow Transplant 2003; 32: 57–63.
   PubMed Web of Science ®Google Scholar
• Williams CD, Goldstone AH, Pearce RM et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996; 14: 2454–2464.
   PubMed Web of Science ®Google Scholar
• Trneny M, Salkova J, Karban J et al. Rituximab, fludarabin and cyclophosphamide followed by high dose therapy with autologous stem cell rescue leads to high molecular remission rate in chronic lymphocytic leukemia patients but relapses are observed. Blood 2004; 104: 948A–949A.
   PubMed Web of Science ®Google Scholar
• Gupta RK, Summers KE, Lister TA. PCR analysis for the t(14;18) translocation in patients with recurrent follicular lymphoma following immunotherapy with rituximab (IDEC-C2B8). Blood 1998; 92: 239A.
   Web of Science ®Google Scholar